Robert  Fenstermaker, MD

Robert Fenstermaker, MD

Roswell Park Comprehensive Cancer Center

Chair of Neurosurgery

Expertise: Brain CancerGlioblastomaNeurosurgery

Chair of Neurosurgery, Roswell Park Cancer Institute
Areas of expertise: Neurosurgery, glioblastoma, brain cancer, immunotherapy, cancer vaccines

No Clipping

No Research/Citations

Roswell Park Opens Phase 2B Randomized Clinical Trial of Promising Brain Cancer Immunotherapy

Roswell Park Comprehensive Cancer Center is the first center to treat patients in a newly opened advanced-stage clinical trial utilizing the brain cancer vaccine SurVaxM, offering a new treatment option for patients who are dealing with a rare but deadly form of the disease. The multicenter randomized clinical trial is sponsored by MimiVax LLC, a company spun off from Roswell Park in 2012.
04-Feb-2022 11:00:07 AM EST

No Quotes

Available for logged-in users onlyLogin HereorRegister

No Video

close
0.08488